Follow The Filings

EWTX Edgewise Therapeutics

Edgewise Therapeutics earnings company data as of 3:59 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by EWTX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All EWTX insider trades
  • $199K bought by 1 insider
  • $2.1M sold by 1 insider outside a trading plan
  • $15.6M sold by 3 insiders under 10b5-1 plans
  1. Joanne M. Donovan CMO
    Planned sale
    $127K 2,919 shares at $43.41 25% of stake
    Traded Aug 13 Filed Aug 14
    ↗
  2. Alan J Russell Chief Scientific Officer
    Planned sale
    $7.9M 200,000 shares at $39.41 89% of stake
    Traded Jul 1 Filed Jul 2
    ↗
  3. Joanne M. Donovan CMO
    Planned sale
    $2.1M 55,230 shares at $37.88 93% of stake
    Traded May 4–5 Filed May 5
    ↗
  4. Joanne M. Donovan CMO
    Planned sale
    $926K 28,662 shares at $32.31 75% of stake
    Traded Apr 1 Filed Apr 2
    ↗
  5. Joanne M. Donovan CMO
    Planned sale
    $685K 21,338 shares at $32.12 69% of stake
    Traded Mar 31 Filed Mar 31
    ↗
  6. Joanne M. Donovan CMO
    Planned sale
    $507K 16,358 shares at $30.98 63% of stake
    Traded Mar 27 Filed Mar 30
    ↗
  7. Badreddin Edris Director
    Planned sale
    $3.4M 115,471 shares at $29.44 85% of stake
    Traded Jan 21 Filed Jan 23
    ↗
  8. Alan J Russell Chief Scientific Officer
    Sale
    $2.1M 100,000 shares at $21.12 81% of stake
    Traded Nov 12, 2025 Filed Nov 13, 2025
    ↗
  9. Jonathan C Fox Director
    Buy
    $199K 10,700 shares at $18.64 +82% to stake
    Traded Nov 11, 2025 Filed Nov 13, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 18 sales to cover taxes, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K/A 9.01 Filing Doc
8-K 2.01,7.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13D/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.